Next Article in Journal
Bacterial and Fungal Co-Infections and Superinfections in a Cohort of COVID-19 Patients: Real-Life Data from an Italian Third Level Hospital
Next Article in Special Issue
A Rare Case of Latent Tuberculosis Reactivation Secondary to a COVID-19 Infection
Previous Article in Journal
Reducing the Risk of Healthcare Associated Infections from Legionella and Other Waterborne Pathogens Using a Water Management for Construction (WMC) Infection Control Risk Assessment (ICRA) Tool
Previous Article in Special Issue
COVID-19 Severity among Healthcare Workers: Overweight Male Physicians at Risk
 
 
Review

Sarilumab Administration in COVID-19 Patients: Literature Review and Considerations

1
Department of Biomedical and Biotechnological Science (BIOMETEC), University of Catania, 95123 Catania, Italy
2
Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, ARNAS Garibaldi Hospital, University of Catania, 95123 Catania, Italy
3
Department of Biomedical and Biotechnological Science, Section of Pharmacology, University of Catania, 95123 Catania, Italy
4
Unit of Clinical Toxicology, Policlinico G. Rodolico, School of Medicine, University of Catania, 95123 Catania, Italy
*
Author to whom correspondence should be addressed.
Academic Editor: Nicola Petrosillo
Infect. Dis. Rep. 2022, 14(3), 360-371; https://doi.org/10.3390/idr14030040
Received: 14 April 2022 / Revised: 8 May 2022 / Accepted: 9 May 2022 / Published: 11 May 2022
(This article belongs to the Special Issue Feature Papers in COVID-19)
Two years have passed since WHO declared a pandemic state for SARS-CoV-2 infection. COVID-19 pathogenesis consists of a first viral phase responsible for early symptoms followed by an inflammatory phase, cytokine-mediated, responsible for late-onset manifestations up to ARDS. The dysregulated immune response has an outstanding role in the progression of pulmonary damage in COVID-19. IL-6, through the induction of pro-inflammatory chemokines and cytokines, plays a key role in the development and maintenance of inflammation, acting as a pioneer of the hyperinflammatory condition and cytokine storm in severe COVID-19. Therefore, drugs targeting both IL-6 and IL-6 receptors have been evaluated in order to blunt the abnormal SARS-CoV-2-induced cytokine release. Sarilumab, a high-affinity anti-IL-6 receptor antibody, may represent a promising weapon to treat the fearsome hyperinflammatory phase by improving the outcome of patients with moderate-to-severe COVID-19 pneumonia. Further prospective and well-designed clinical studies with larger sample sizes and long-term follow-up are needed to assess the efficacy and the safety of this therapeutic approach to achieve improved outcomes in COVID-19. View Full-Text
Keywords: COVID-19; cytokines; IL-6; IL-6R; sarilumab COVID-19; cytokines; IL-6; IL-6R; sarilumab
Show Figures

Figure 1

MDPI and ACS Style

Marino, A.; Munafò, A.; Augello, E.; Bellanca, C.M.; Bonomo, C.; Ceccarelli, M.; Musso, N.; Cantarella, G.; Cacopardo, B.; Bernardini, R. Sarilumab Administration in COVID-19 Patients: Literature Review and Considerations. Infect. Dis. Rep. 2022, 14, 360-371. https://doi.org/10.3390/idr14030040

AMA Style

Marino A, Munafò A, Augello E, Bellanca CM, Bonomo C, Ceccarelli M, Musso N, Cantarella G, Cacopardo B, Bernardini R. Sarilumab Administration in COVID-19 Patients: Literature Review and Considerations. Infectious Disease Reports. 2022; 14(3):360-371. https://doi.org/10.3390/idr14030040

Chicago/Turabian Style

Marino, Andrea, Antonio Munafò, Egle Augello, Carlo Maria Bellanca, Carmelo Bonomo, Manuela Ceccarelli, Nicolò Musso, Giuseppina Cantarella, Bruno Cacopardo, and Renato Bernardini. 2022. "Sarilumab Administration in COVID-19 Patients: Literature Review and Considerations" Infectious Disease Reports 14, no. 3: 360-371. https://doi.org/10.3390/idr14030040

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop